This section is dedicated to rapid collaborative reviews and HTA reports on diagnostic tests for the detection of SARS-CoV-2 requested to inform timely national policy/decision-making.
EUnetHTA Rapid Collaborative Reviews
|Project ID||Title||Publication of Final Review||Author||Co-Author||Publication of Project Plan|
|RCROT01*||Rapid Collaborative Review on the role of antibody tests for novel coronavirus SARS-CoV-2 in the management of the current pandemic||23.06.20||RER||IQWiG, HTW||12.05.20|
|RCROT02||Diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19||04.12.20 (revised 14.12.20)||HTW||HIS, Austrian Social Insurance – Dachverband der Sozialversicherungsträger (formerly HVB)||31.07.20 (revised 08.10.20)|
*Note: Since the publication of this Rapid Collaborative Review on the 23rd June, several good quality systematic reviews addressing the question on diagnostic use of SARS-COV-2 antibody tests in asymptomatic and symptomatic patients have been published. These more recent reviews have confirmed our findings and the limitations of the screening and diagnostic use of these tests, due to how antibodies develop and the time it takes to become detectable. While the retrieved studies in our review showed antibody tests are “responsive” to be used in seroprevalence studies, the current knowledge on the natural history of the disease – namely virus clearance and immunity – is still too limited to allow investigation of a potential role of antibody tests in these intended uses.
In light of the above, the Assessment Team has agreed not to proceed with further updates of this review.
National HTA Organisation Diagnostics Reports
This will be a ‘work in progress’ as we accrue data and as the response to Covid-19 evolves, so please bookmark this page for quick reference as we build out the links.
For any questions, please contact the EUnetHTA Secretariat at email@example.com